MDWD (MediWound) Institutional Ownership : 41.18% (As of Apr. 02, 2025)

View and export this data going back to 2014. Start your Free Trial

What is MediWound Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MediWound's institutional ownership is 41.18%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MediWound's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MediWound's Float Percentage Of Total Shares Outstanding is 82.04%.

MediWound Institutional Ownership Historical Data

The historical data trend for MediWound's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediWound Institutional Ownership Chart

MediWound Historical Data

The historical data trend for MediWound can be seen below:

	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28
Institutional Ownership	4.41	9.10	12.06	10.39	11.76	11.92	11.72	11.48	11.60	11.48

MediWound Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

MediWound Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediWound Ltd (NAS:MDWD) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

M8W:Germany

Address

42 Hayarkon Street, Yavne, ISR, 8122745

Website

https://www.mediwound.com

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.